Multiple TMA-aided CRISPR/Cas13a platform for highly sensitive detection of IL-15 to predict immunotherapeutic response in nasopharyngeal carcinoma

BACKGROUND: Immune checkpoint inhibitors (ICIs)-based treatments have been recommended as the first line for refractory recurrent and/or metastatic nasopharyngeal carcinoma (NPC) patients, yet responses vary, and predictive biomarkers are urgently needed. We selected serum interleukin-15 (sIL-15) ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ya-Xian, Xing, Shan, Wang, Yu, Tian, Bo-Yu, Wu, Meng, Wang, Xue-Ping, Huang, Qi, He, Xia, Chen, Shu-Lin, Li, Xiao-Hui, Zeng, Mu-Sheng, Liu, Wan-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401221/
https://www.ncbi.nlm.nih.gov/pubmed/37536937
http://dx.doi.org/10.1136/jitc-2022-006552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401221/
https://www.ncbi.nlm.nih.gov/pubmed/37536937
http://dx.doi.org/10.1136/jitc-2022-006552

Ejemplares similares